To evaluate and compare the performance of various plasma pTau217 assays for diagnosing Alzheimer's disease, emphasizing their clinical relevance.
Key Findings:
All plasma pTau217 assays demonstrated excellent performance with AUCs ranging from 0.91 to 0.97, indicating strong diagnostic potential.
The %pTau217WashU assay outperformed other assays in detecting Aβ-PET positivity and was unaffected by kidney function, highlighting its clinical utility.
Mass spectrometry assays, while accurate, may not be practical for widespread clinical use due to cost and throughput limitations, which could hinder their adoption.
Immunoassays like pTau217Lilly and pTau217ALZpath showed varying performance, with some outperforming FDA-approved CSF biomarkers, suggesting potential for clinical application.
Interpretation:
The findings suggest that while plasma pTau217 assays are promising for Alzheimer's diagnostics, the choice of assay may depend on practical considerations such as cost, accessibility, and the specific clinical context, which are crucial for implementation.
Limitations:
The studies primarily focused on specific cohorts, which may limit generalizability and applicability to broader populations.
Performance comparisons were not exhaustive for all available assays, particularly newer platforms, which may affect the comprehensiveness of the findings.
Conclusion:
The %pTau217WashU assay appears to be the most effective for clinical use, but the choice of assay should consider practical aspects of implementation in clinical settings, ensuring accessibility and cost-effectiveness.
